Anti-Human IL12+IL23 Recombinant Antibody (Ustekinumab) (CAT#: TAB-063)
Recombinant monoclonal antibody to IL12+IL23. Ustekinumab (INN, experimental name CNTO 1275, proprietary commercial name Stelara, Centocor) is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
Specific Inquiry
Figure 2 Mutational analyses of ustekinumab epitope.
(a) Binding of human p40 and epitope variants to ustekinumab. Amino acids E45, E59, D62, M23, L40, and S43 are important IL-12/IL-23p40 residues for ustekinumab binding by ELISA. (b) Ustekinumab binding of p40 mutants (E45A, E59A, D62A, and triple combination) that disrupt antibody/antigen salt bridges by competition ELISA. Hu p40,wild-type humanp40; C177S, chimeric human/mouse p40 protein (hybrid D1-mouseD2-humanD3)with the free Cys177 mutated to Ser. The hybrid D1 domain is a mouse sequence, with all ustekinumab epitope residues substituted at the corresponding positions. (c) Ustekinumab binding of human/mouse swap mutants by competition ELISA. Hu p40 and C177S are the same as (b). P1, P2, and P3 represent human-to-mouse changes in the C177S hybrid D1 domain (G61L, 40LDQSSEVL47→40SDQRHGVI47, and M23T/Q56T, respectively). P1+P2 is a combination of P1 and P2 mutations.
Luo, J., Wu, S. J., Lacy, E. R., Orlovsky, Y., Baker, A., Teplyakov, A., ... & Benson, J. (2010). Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. Journal of molecular biology, 402(5), 797-812.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- IgG1 - kappa
- Specificity
- Tested positive against native human antigen.
- Species Reactivity
- Human
- Applications
- WB, FuncS, IF, Neut, ELISA, FC, IP
- Trade name
- stelara
- CAS
- 815610-63-0
- Generic Name
- Ustekinumab
- Biological Half-Life
- 15–32 days (average 3 weeks)
- ATC Code
- L04AC05
- UNII
- FU77B4U5Z0
- ChEMBL
- CHEMBL1201835
- MW
- 145.64 kDa
- Related Disease
- Inflammatory diseases
Product Property
- Purity
- >95%, by SDS-PAGE with silver staining, under reducing conditions.
- Storage
- Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
Applications
- Application Notes
- The IL12+IL23 antibody has been reported in applications of Activ, ELISA.
Target
- Alternative Names
- Ustekinumab;stelara;815610-63-0;CNTO 1275;TT-20;C01275;CNTO 1275;Centocor;Stelara;CNTO 1275;IL12B;interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40);NKSF2;interleukin-12 subunit beta;CLMF;CLMF2;cytoto
Related Resources
Please refer to Ustekinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Ustekinumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Ustekinumab"
Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-063)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. It is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
DrugMonitor™ Anti-Ustekinumab Antibody (VS-1224-YC1271)Ustekinumab is a targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The DrugMonitor™ Anti-Ustekinumab Antibody (VS-1224-YC1271) is an anti-drug antibody (ADA) against Ustekinumab. This drug-based antibody is raised in mice immunized with the Ustekinumab. The anti-Ustekinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Ustekinumab in samples.
See other products for "IL12+IL23"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single Domain Antibody Products
Human Antibody Products
ADCC Enhanced Antibody Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-1410-VHH | Recombinant Anti-Human IL12+IL23 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-063. Click the button above to contact us or submit your feedback about this product.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-063, RRID: AB_3111784)
Copy citation
Popular products with customers
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: WB, IF, IP, Neut, FuncS, ELISA, FC
Application: WB, IP, IF, FuncS, FC, Neut, ELISA
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: WB, ELISA, FC, IHC, IP
-1.jpg)
Application: FC, FuncS, IA, IF, IP, IHC
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
